Compare, Analyse Aurobindo Pharma with TEVA PHARMACEUTICAL INDUSTRIES LTD. - Israel - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AUROBINDO PHARMA vs TEVA PHARMA (Israel) - Comparison Results

AUROBINDO PHARMA     Change

Aurobindo Pharma is one of India's top 5 pharma companies in terms of turnover, and has presence in the generic and Active Pharmaceutical Ingredients (API) segments. The company's robust product portfolio is spread across 6 product areas, including a... More

TEVA PHARMA (Israel)
   Change

Teva Pharmaceuticals, established in 1901, is a global pharmaceutical company. The company is into development, production and marketing of a wide range of specialty medicines, generic and OTC products, active pharmaceutical ingredients (API) and nov... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 AUROBINDO PHARMA   TEVA PHARMA
EQUITY SHARE DATA
    AUROBINDO PHARMA
Mar-19
TEVA PHARMA
Dec-13
AUROBINDO PHARMA/
TEVA PHARMA
5-Yr Chart
Click to enlarge
High Rs8303,185-   
Low Rs5272,767-   
Sales per share (Unadj.) Rs333.91,827.8-  
Earnings per share (Unadj.) Rs40.4114.2-  
Cash flow per share (Unadj.) Rs51.8261.9-  
Dividends per share (Unadj.) Rs2.5099.95-  
Dividend yield (eoy) %0.43.4 11.0%  
Book value per share (Unadj.) Rs237.12,030.3-  
Shares outstanding (eoy) m585.91848.00-   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x2.01.6 124.8%   
Avg P/E ratio x16.826.1 64.5%  
P/CF ratio (eoy) x13.111.4 115.4%  
Price / Book Value ratio x2.91.5 195.3%  
Dividend payout %6.287.5 7.1%   
Avg Mkt Cap Rs m397,5692,523,394 15.8%   
No. of employees `00017.944.9 39.7%   
Total wages/salary Rs m25,8490-   
Avg. sales/employee Rs Th10,956.934,485.7 31.8%   
Avg. wages/employee Rs Th1,447.70-   
Avg. net profit/employee Rs Th1,324.32,154.3 61.5%   
INCOME DATA
Net Sales Rs m195,6361,549,958 12.6%  
Other income Rs m1,5530-   
Total revenues Rs m197,1891,549,958 12.7%   
Gross profit Rs m39,519424,457 9.3%  
Depreciation Rs m6,680125,285 5.3%   
Interest Rs m2,62630,444 8.6%   
Profit before tax Rs m31,767268,729 11.8%   
Minority Interest Rs m271,221 2.2%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-881-176,406 0.5%   
Tax Rs m7,269-3,281 -221.5%   
Profit after tax Rs m23,64596,825 24.4%  
Gross profit margin %20.227.4 73.8%  
Effective tax rate %22.9-1.2 -1,874.1%   
Net profit margin %12.16.2 193.5%  
BALANCE SHEET DATA
Current assets Rs m153,6451,046,836 14.7%   
Current liabilities Rs m120,429912,930 13.2%   
Net working cap to sales %17.08.6 196.5%  
Current ratio x1.31.1 111.3%  
Inventory Days Days13591 148.9%  
Debtors Days Days6496 66.4%  
Net fixed assets Rs m103,909506,251 20.5%   
Share capital Rs m5863,815 15.4%   
"Free" reserves Rs m138,3220-   
Net worth Rs m138,9081,721,710 8.1%   
Long term debt Rs m1,800792,528 0.2%   
Total assets Rs m264,5443,542,151 7.5%  
Interest coverage x13.19.8 133.3%   
Debt to equity ratio x00.5 2.8%  
Sales to assets ratio x0.70.4 169.0%   
Return on assets %9.93.6 276.4%  
Return on equity %17.05.6 302.7%  
Return on capital %23.84.9 483.4%  
Exports to sales %49.60-   
Imports to sales %18.80-   
Net fx Rs m56,7270-   
CASH FLOW
From Operations Rs m16,220246,983 6.6%  
From Investments Rs m-28,768-87,516 32.9%  
From Financial Activity Rs m19,191-296,273 -6.5%  
Net Cashflow Rs m6,656-136,806 -4.9%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for TEVA PHARMA (Israel) is United States Dollars. All data has been converted at 76.3 Rs / USD

Compare AUROBINDO PHARMA With: ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  

Compare AUROBINDO PHARMA With: STRIDES PHARMA SCIENCE  ABBOTT INDIA  FDC LTD.  NOVARTIS  SUVEN LIFESCIENCES  



Today's Market

Sensex Crashes 1,203 Points; IT and Banking Stocks Witness Selling(Closing)

Indian share markets extended losses in the first trading session of FY21, as the number of coronavirus cases in the country continued to rise.

Related Views On News

AUROBINDO PHARMA Announces Quarterly Results (3QFY20); Net Profit Down 0.5% (Quarterly Result Update)

Feb 7, 2020 | Updated on Feb 7, 2020

For the quarter ended December 2019, AUROBINDO PHARMA has posted a net profit of Rs 7 bn (down 0.5% YoY). Sales on the other hand came in at Rs 58 bn (up 10.1% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

AUROBINDO PHARMA Announces Quarterly Results (2QFY20); Net Profit Up 4.6% (Quarterly Result Update)

Nov 15, 2019 | Updated on Nov 15, 2019

For the quarter ended September 2019, AUROBINDO PHARMA has posted a net profit of Rs 6 bn (up 4.6% YoY). Sales on the other hand came in at Rs 56 bn (up 17.9% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

AUROBINDO PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Nov 6, 2019 | Updated on Nov 6, 2019

Here's an analysis of the annual report of AUROBINDO PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of AUROBINDO PHARMA. Also includes updates on the valuation of AUROBINDO PHARMA.

AUROBINDO PHARMA 2017-18 Annual Report Analysis (Annual Result Update)

Dec 19, 2018 | Updated on Dec 19, 2018

Here's an analysis of the annual report of AUROBINDO PHARMA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of AUROBINDO PHARMA. Also includes updates on the valuation of AUROBINDO PHARMA.

More Views on News

Most Popular

Sorry Warren Buffett, I'm Following This Man Instead of You in 2020 (The 5 Minute Wrapup)

Mar 30, 2020

This man warned of an impending market correction while everyone else was celebrating the renewed optimism in early 2020...

A Big Trading Opportunity is Coming Your Way Soon (Fast Profits Daily)

Mar 25, 2020

I see a big opportunity to make fast profits on the horizon.

The Biggest Trading Opportunity of 2020 is Here...

Mar 26, 2020

India's #1 trader, Vijay Bhambwani, talks about a hugely profitable trading opportunity which you must know about today!

Coronavirus Sell-off Is a Perfect Time to 'Lockdown' this 'Crorepati' Stock (Profit Hunter)

Mar 24, 2020

Coronavirus crisis and panic selling has brought this quality smallcap to multiyear lows, making it a great bargain.

Lockdown! Now the Bailout... (The Honest Truth)

Mar 25, 2020

Ajit Dayal on what India should do to manage the coronavirus impact on the economy.

More

How to Trade the
Coronavirus Crash

Coronavirus Crash
Get this special report, authored by Equitymaster's top analysts, now.
We will never sell or rent your email id.
Please read our Terms

OUR TOP 5 IDEAS

How to Trade the Coronavirus Crash - Download this FREE Report Now
Are You Making One of These 15 Costly Mistakes While Investing. Learn more!
A Guide to some of the Most Lucrative Stocks in the Market. Download For Free!
Free Report: The Secret to Increasing Your Trading Profits Daily!
Find Out Our Top 7 Bluechips for 2020 Virtually FREE. Click Here Now!

AUROBINDO PHARMA SHARE PRICE


Apr 1, 2020 (Close)

TRACK AUROBINDO PHARMA

  • Track your investment in AUROBINDO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON AUROBINDO PHARMA

AUROBINDO PHARMA - VENUS REMEDIES COMPARISON

COMPARE AUROBINDO PHARMA WITH

OTHER USEFUL LINKS

MARKET STATS